You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Thursday, April 29, 2021
11 am EDT | 8 am PDT | 3 pm GMT

 

Abstract

XCell ATF® technology can expand bioprocess facility capacity and throughput with cell densities up 300 x 106 VCD/mL. The newly launched XCell™ Lab Controller System accelerates development of robust intensified processes at volumes as low as 0.5L, reducing media costs per run and facilitating advancement to manufacturing. The benefits of key features such as a 0.5L single-use device, permeate pressure recording, a pump-based control logic loop, support for two devices per controller and a modern smartphone-like software interface will be discussed.

Speaker

Earl Pineda headshot.JPGEarl Pineda 
Sr. Manager, Upstream Field Applications EU/APAC

Earl Pineda is currently managing the Repligen Field Applications Scientists team for Europe and Asia. Earl has been in the biotech industry for 20 years, working at Refine Technologies and at Repligen Corporation, helping hundreds of companies successfully implement the XCell ATF® technology in Europe and Asia. Earl previously worked at major biotech companies such as Amgen, Novartis and Biomarin, performing different research functions in process development, MSAT and technical transfer. An expert in perfusion processes, Earl has experience with cell retention technologies, including XCell ATF®, KrosFlo® TFF, gravitational cell settlers, acoustic cell retention, centrifugation, and microcarrier-based systems. At Biomarin, Earl helped develop several commercial perfusion processes for Aldurazyme and Naglazyme. At Refine and Repligen, Earl helped develop the XCell ATF® Single-use System and designed user interfaces for several ATF controllers.